Alkermes Plc - Company Profile
Powered by
All the data and insights you need on Alkermes Plc in one report.
- Save hours of research time and resources with
our up-to-date Alkermes Plc Strategy Report
- Understand Alkermes Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Alkermes Plc (Alkermes) is an integrated biopharmaceutical company with focus on developing novel therapies for the treatment of chronic diseases including CNS disorders, cancer and addiction. Focused R&D activities, increase in product sales and CNS product portfolio are the major strengths of the company, even as overdependence on the US could be a cause for concern to the company. Limited distributors for revenue, increasing competitive pressure together with changing government regulations could affect the company’s growth and profitability. However, the company could capture growth opportunities through various strategic initiatives, the market potential for Schizophrenia, and orphan drug designation for nemvaleukin alfa.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer